证券日报网讯蓝帆医疗（002382）8月5日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东人数为76827户。 ...

从8月5日公开信息显示，蓝帆医疗截至2025年7月31日公司股东户数为7.68万户，较上期（2025年7月18日）增加374户， 增幅为0.49%，变化不大。 统计日期股东户数户均持股数（万股）户均持股市值（万元） 2025/07/31768271.318.352025/07/18764531.328.212025/06/20783771.286.872025/03/31810341.246.152025/03/20821571.236.39 来源：金融界 从数据对比来看，蓝帆医疗户均持股数从上期1.32万股下降至本期1.31万股，户均持股市值从上期8.21万元上升至本期 8.35万元。上述区间，蓝帆医疗股价累计下跌1.23%。 截至发稿，蓝帆医疗报6.41元，下跌0.31%，市值64.56亿元。 最新5个统计日期，蓝帆医疗股东户数变动如下： ...

Core Viewpoint - Bluefan Medical (002382) has shown a mixed performance in terms of stock price and financial metrics, with recent data indicating a decline in stock price and varying trends in capital flow [1][2]. Group 1: Stock Performance - As of August 4, 2025, Bluefan Medical's stock closed at 6.43 yuan, down 0.31% with a turnover rate of 2.09% and a trading volume of 208,800 hands, amounting to a transaction value of 132 million yuan [1]. - The net outflow of main funds on August 4 was 8.055 million yuan, accounting for 6.09% of the total transaction value, while retail investors saw a net inflow of 10.9947 million yuan, representing 8.31% of the total transaction value [1]. Group 2: Financial Metrics - Bluefan Medical's total market value is 6.476 billion yuan, which is below the industry average of 11.617 billion yuan, ranking 54 out of 122 in the medical device industry [2]. - The company's net profit for the first quarter of 2025 was 77.0223 million yuan, reflecting a significant year-on-year increase of 177.86%, while the main revenue was 1.478 billion yuan, up 1.59% year-on-year [2]. - The company's gross profit margin stands at 17.17%, significantly lower than the industry average of 51.11%, ranking 116 out of 122 [2].

Overview - The company, Bluestar Medical Co., Ltd., plans to apply for a total credit limit of up to RMB 1.71 billion for 2025, which includes various types of financing such as working capital loans and bank guarantees [1][3] Credit and Guarantee Situation - The company and its subsidiaries will provide guarantees totaling no more than RMB 1.71 billion, with RMB 1.544 billion allocated for subsidiaries with a debt-to-asset ratio below 70% and RMB 166 million for those at or above 70% [1][3] - The guarantee period is valid for 12 months from the date of the shareholders' meeting resolution [1] Recent Developments - Recently, the company applied for a credit limit of up to RMB 50 million from Zheshang Bank, securing it with a pledge of a RMB 50 million time deposit [3][7] - This guarantee does not exceed the approved limit from the recent board and shareholders' meetings, thus no additional meetings are required for approval [3] Financial Data - As of the announcement date, the total maximum guarantee amount for the company and its subsidiaries is RMB 3,803.58 million, which accounts for 46.46% of the company's audited net assets for 2024 [8] - The company has no overdue guarantees or any litigation related to guarantees [9] Company Information - Bluestar Medical Co., Ltd. was established on December 2, 2002, with a registered capital of RMB 1,007.13 million [4][5] - The company specializes in the production of PVC gloves, nitrile gloves, and various medical devices [5]

7月31日，沪深两融数据显示，蓝帆医疗获融资买入额0.10亿元，居两市第2708位，当日融资偿还额0.18 亿元，净卖出843.38万元。 最近三个交易日，29日-31日，蓝帆医疗分别获融资买入0.13亿元、0.10亿元、0.10亿元。 融券方面，当日融券卖出0.81万股，净卖出0.04万股。 来源：金融界 ...

证券日报网讯7月31日晚间，蓝帆医疗（002382）发布公告称，截至本次担保全部发生后，公司及子公 司的担保最高额为380，357.86万元人民币(外币担保余额均按照2025年7月31日央行公布的汇率折算)， 占公司2024年度经审计净资产的46.46%，未超过2024年度经审计净资产的50%。公司及子公司对合并报 表外单位提供的担保总余额为850万元人民币，占公司2024年度经审计净资产的0.10%。公司及子公司 无逾期对外担保、无涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-063 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事 会第十六次会议、2024年12月23日召开了2024年第三次临时股东大会，审议并通过了 《关于2025年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2025 年度拟向银行等金融机构申请综合授信总额不超过人民币17.10亿元，授信品种包括但 不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综合 授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子公司 生产运营对资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述综合 授信提供担保额度总计不超过人民币17.10亿元，其中，预计为公司及资产负债率70% 以下（ ...

Group 1 - The core viewpoint of the article is the establishment of Bluefan Emergency Technology (Wuhan) Co., Ltd. as a new business entity aimed at expanding the domestic emergency rescue market in China [1] - The emergency rescue division of Bluefan Medical has developed a product portfolio that covers various fields and scenarios, including home, vehicle, public places, outdoor activities, travel, disaster relief, and pet care [1] - The company has completed most of the self-manufacturing and supply chain integration for its products, with the core product, the first aid kit, achieving an annual production capacity of 20 million sets [1]

最近三个交易日，28日-30日，蓝帆医疗分别获融资买入0.18亿元、0.13亿元、0.10亿元。 融券方面，当日融券卖出1.75万股，净卖出0.86万股。 来源：金融界 7月30日，沪深两融数据显示，蓝帆医疗获融资买入额0.10亿元，居两市第2304位，当日融资偿还额0.10 亿元，净买入59.01万元。 ...

Group 1 - The core viewpoint of the article is the establishment of a new company, 蓝帆应急科技(武汉)有限公司, by 蓝帆医疗 to expand its presence in the domestic emergency rescue market [1] - The new company will focus on various fields and scenarios including home, vehicle, public places, outdoor activities, travel, disaster relief, and pet care [1] - The emergency rescue division has completed most of its product manufacturing and supply chain integration, with a core product capacity of 20 million emergency kits per year [1]